Published in J Mol Diagn on August 22, 2012
Coming of age: ten years of next-generation sequencing technologies. Nat Rev Genet (2016) 2.48
Towards clinical molecular diagnosis of inherited cardiac conditions: a comparison of bench-top genome DNA sequencers. PLoS One (2013) 1.12
A statewide survey of practitioners to assess knowledge and clinical practices regarding hereditary breast and ovarian cancer. Genet Test Mol Biomarkers (2013) 1.03
Evaluation and optimisation of indel detection workflows for ion torrent sequencing of the BRCA1 and BRCA2 genes. BMC Genomics (2014) 0.95
Ion Torrent sequencing for conducting genome-wide scans for mutation mapping analysis. Mamm Genome (2013) 0.87
A reliable method for the detection of BRCA1 and BRCA2 mutations in fixed tumour tissue utilising multiplex PCR-based targeted next generation sequencing. BMC Clin Pathol (2015) 0.85
Comparison of targeted next-generation sequencing and Sanger sequencing for the detection of PIK3CA mutations in breast cancer. BMC Clin Pathol (2015) 0.84
Comprehensive massive parallel DNA sequencing strategy for the genetic diagnosis of the neuro-cardio-facio-cutaneous syndromes. Eur J Hum Genet (2014) 0.83
Detection of inherited mutations for hereditary cancer using target enrichment and next generation sequencing. Fam Cancer (2015) 0.82
Addressing health disparities in Hispanic breast cancer: accurate and inexpensive sequencing of BRCA1 and BRCA2. Gigascience (2015) 0.81
New recurrent BRCA1/2 mutations in Polish patients with familial breast/ovarian cancer detected by next generation sequencing. BMC Med Genomics (2015) 0.81
New challenges for BRCA testing: a view from the diagnostic laboratory. Eur J Hum Genet (2016) 0.80
Validation of a semiconductor next-generation sequencing assay for the clinical genetic screening of CFTR. Mol Genet Genomic Med (2015) 0.79
First application of next-generation sequencing in Moroccan breast/ovarian cancer families and report of a novel frameshift mutation of the BRCA1 gene. Oncol Lett (2016) 0.78
Ion Torrent sequencing as a tool for mutation discovery in the flax (Linum usitatissimum L.) genome. Plant Methods (2015) 0.78
Validation of multiple single nucleotide variation calls by additional exome analysis with a semiconductor sequencer to supplement data of whole-genome sequencing of a human population. BMC Genomics (2014) 0.77
Predictive Factors for BRCA1 and BRCA2 Genetic Testing in an Asian Clinic-Based Population. PLoS One (2015) 0.76
Bioinformatic Challenges in Clinical Diagnostic Application of Targeted Next Generation Sequencing: Experience from Pheochromocytoma. PLoS One (2015) 0.75
Improved Efficiency and Reliability of NGS Amplicon Sequencing Data Analysis for Genetic Diagnostic Procedures Using AGSA Software. Biomed Res Int (2016) 0.75
GATK hard filtering: tunable parameters to improve variant calling for next generation sequencing targeted gene panel data. BMC Bioinformatics (2017) 0.75
Sequence specific sorting of DNA molecules with FACS using 3dPCR. Sci Rep (2017) 0.75
Simultaneous detection of BRCA mutations and large genomic rearrangements in germline DNA and FFPE tumor samples. Oncotarget (2016) 0.75
Integration of external signaling pathways with the core transcriptional network in embryonic stem cells. Cell (2008) 28.29
A library of yeast transcription factor motifs reveals a widespread function for Rsc3 in targeting nucleosome exclusion at promoters. Mol Cell (2008) 4.49
Fate tracing of mature hepatocytes in mouse liver homeostasis and regeneration. J Clin Invest (2011) 2.83
An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma. Cancer Cell (2011) 2.78
Integrating copy number polymorphisms into array CGH analysis using a robust HMM. Bioinformatics (2006) 2.50
Digital pathology: exploring its applications in diagnostic surgical pathology practice. Pathology (2010) 2.05
Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J Hepatol (2008) 1.87
Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer. J Natl Cancer Inst (2010) 1.83
Predicting spatial and temporal gene expression using an integrative model of transcription factor occupancy and chromatin state. PLoS Comput Biol (2012) 1.71
Identification of circulating microRNA signatures for breast cancer detection. Clin Cancer Res (2013) 1.67
MicroRNAs control hepatocyte proliferation during liver regeneration. Hepatology (2010) 1.64
A molecular classification of papillary renal cell carcinoma. Cancer Res (2005) 1.60
Genomic structure of human OKL38 gene and its differential expression in kidney carcinogenesis. J Biol Chem (2003) 1.58
Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol (2003) 1.55
Comparison of the UCLA Integrated Staging System and the Leibovich score in survival prediction for patients with nonmetastatic clear cell renal cell carcinoma. Urology (2010) 1.52
Genome-wide association studies reveal genetic variants in CTNND2 for high myopia in Singapore Chinese. Ophthalmology (2010) 1.44
Conservation of breast cancer molecular subtypes and transcriptional patterns of tumor progression across distinct ethnic populations. Clin Cancer Res (2004) 1.44
Diagnostic issues in second opinion consultations in prostate pathology. Pathology (2010) 1.42
A rare case of localised AA-type amyloidosis of the ureter with spheroids of amyloid. Singapore Med J (2012) 1.39
Significance of Plk1 regulation by miR-100 in human nasopharyngeal cancer. Int J Cancer (2010) 1.38
Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer. Mod Pathol (2009) 1.32
Hormone receptor and c-ERBB2 status in distant metastatic and locally recurrent breast cancer. Pathologic correlations and clinical significance. Am J Clin Pathol (2010) 1.29
Do primary mammary osteosarcoma and chondrosarcoma exist? A review of a large multi-institutional series of malignant matrix-producing breast tumours. Breast (2012) 1.27
Triple negative breast cancer: outcome correlation with immunohistochemical detection of basal markers. Am J Surg Pathol (2010) 1.25
Solid pseudopapillary tumour of the pancreas. ANZ J Surg (2003) 1.19
Breast-cancer risk in families with mutations in PALB2. N Engl J Med (2014) 1.17
Identification of novel lung genes in bronchial epithelium by serial analysis of gene expression. Am J Respir Cell Mol Biol (2006) 1.13
Succinate dehydrogenase (SDH)-deficient renal carcinoma: a morphologically distinct entity: a clinicopathologic series of 36 tumors from 27 patients. Am J Surg Pathol (2014) 1.11
The pathology of dengue hemorrhagic fever. Semin Diagn Pathol (2007) 1.10
Improving indel detection specificity of the Ion Torrent PGM benchtop sequencer. PLoS One (2012) 1.10
Genomic expression and single-nucleotide polymorphism profiling discriminates chromophobe renal cell carcinoma and oncocytoma. BMC Cancer (2010) 1.08
MicroRNA-494 within an oncogenic microRNA megacluster regulates G1/S transition in liver tumorigenesis through suppression of mutated in colorectal cancer. Hepatology (2013) 1.07
Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy. Support Care Cancer (2010) 1.07
Recurrent phyllodes tumours of the breast: pathological features and clinical implications. ANZ J Surg (2006) 1.06
Cancer stem cell markers are associated with adverse biomarker profiles and molecular subtypes of breast cancer. Breast Cancer Res Treat (2012) 1.06
Multiple dysregulated pathways in nasopharyngeal carcinoma revealed by gene expression profiling. Int J Cancer (2006) 1.04
Utility of mammaglobin and gross cystic disease fluid protein-15 (GCDFP-15) in confirming a breast origin for recurrent tumors. Breast (2010) 1.04
Spindle cell lesions of the breast--the pathologic differential diagnosis. Breast Cancer Res Treat (2007) 1.03
Effect of blast exposure on the brain structure and cognition in Macaca fascicularis. J Neurotrauma (2011) 1.01
A molecular signature of the Nottingham prognostic index in breast cancer. Cancer Res (2004) 1.01
Nucleophosmin interacts with HEXIM1 and regulates RNA polymerase II transcription. J Mol Biol (2008) 1.01
c-erbB-2 (HER-2/neu) immunohistochemistry in invasive breast cancer: is there concordance between standard sections and tissue microarrays? Pathology (2006) 1.01
The Karakiewicz nomogram is the most useful clinical predictor for survival outcomes in patients with localized renal cell carcinoma. Cancer (2011) 1.00
p53-Independent regulation of p21Waf1/Cip1 expression and senescence by PRMT6. Nucleic Acids Res (2012) 0.99
An ultra-high-throughput spiral microfluidic biochip for the enrichment of circulating tumor cells. Analyst (2014) 0.99
Global evolutionary trend of the prevalence of primary glomerulonephritis over the past three decades. Nephron Clin Pract (2010) 0.99
Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer. J Clin Oncol (2003) 0.98
DEAD-box helicase DP103 defines metastatic potential of human breast cancers. J Clin Invest (2014) 0.97
Measurement properties of the English and Chinese versions of the Functional Assessment of Cancer Therapy-Breast (FACT-B) in Asian breast cancer patients. Breast Cancer Res Treat (2011) 0.97
Core promoter recognition complex changes accompany liver development. Proc Natl Acad Sci U S A (2011) 0.97
Inference of transcriptional regulation relationships from gene expression data. Bioinformatics (2003) 0.97
Sclerosing polycystic adenosis of the parotid gland: report of a bifocal, paucicystic variant with ductal carcinoma in situ and pronounced stromal distortion mimicking invasive carcinoma. Head Neck Pathol (2011) 0.97
Mixed epithelial and stromal tumour (MEST) of the kidney: a clinicopathological report of three cases. Pathology (2009) 0.96
Evaluation of nanofluidics technology for high-throughput SNP genotyping in a clinical setting. J Mol Diagn (2011) 0.96
Evaluation and optimisation of indel detection workflows for ion torrent sequencing of the BRCA1 and BRCA2 genes. BMC Genomics (2014) 0.95
TP53 genomic status regulates sensitivity of gastric cancer cells to the histone methylation inhibitor 3-deazaneplanocin A (DZNep). Clin Cancer Res (2012) 0.95
Inferring direct regulatory targets of a transcription factor in the DREAM2 challenge. Ann N Y Acad Sci (2009) 0.94
Is triple immunostaining with 34betaE12, p63, and racemase in prostate cancer advantageous? A tissue microarray study. Am J Clin Pathol (2007) 0.94
Insulin growth factor receptor-1 expression and loss of PTEN protein predict early recurrence in triple-negative breast cancer. Histopathology (2012) 0.94
Atypia in inverted urothelial papillomas: pathology and prognostic significance. Hum Pathol (2004) 0.93
Sarcomatoid renal cell carcinoma metastatic to the breast: report of a case with diagnosis on fine needle aspiration cytology. Acta Cytol (2007) 0.93
Predictors of phyllodes tumours on core biopsy specimens of fibroepithelial neoplasms. Histopathology (2010) 0.93
Androgen receptor expression shows distinctive significance in ER positive and negative breast cancers. Ann Surg Oncol (2014) 0.91
TRARESA: a tissue microarray-based hospital system for biomarker validation and discovery. Pathology (2008) 0.91
Targets of genome copy number reduction in primary breast cancers identified by integrative genomics. Genes Chromosomes Cancer (2007) 0.91
The English and Chinese versions of the five-level EuroQoL Group's five-dimension questionnaire (EQ-5D) were valid and reliable and provided comparable scores in Asian breast cancer patients. Support Care Cancer (2012) 0.91
Flat epithelial atypia: concepts and controversies of an intraductal lesion of the breast. Pathology (2005) 0.91
Juxtaglomerular cell tumor: a morphological, immunohistochemical and genetic study of six cases. Hum Pathol (2012) 0.90
Delta-aminolevulinic acid dehydratase (ALAD) polymorphism and susceptibility of workers exposed to inorganic lead and its effects on neurobehavioral functions. Neurotoxicology (2004) 0.90
Validation of the Gail model for predicting individual breast cancer risk in a prospective nationwide study of 28,104 Singapore women. Breast Cancer Res (2012) 0.90
Hypericin-photodynamic therapy (PDT) using an alternative treatment regime suitable for multi-fraction PDT. J Photochem Photobiol B (2005) 0.89
CHEK2*1100delC screening of Asian women with a family history of breast cancer is unwarranted. J Clin Oncol (2008) 0.88
BRCA1 and BRCA2 mutations in an Asian clinic-based population detected using a comprehensive strategy. Cancer Epidemiol Biomarkers Prev (2007) 0.88
Breast carcinoma in women 35 years and younger: a pathological study. Pathology (2006) 0.88
Effect of CYP3A4 inducer dexamethasone on hepatotoxicity of lapatinib: clinical and in vitro evidence. Breast Cancer Res Treat (2012) 0.88
Incidence of febrile neutropenia among early-stage breast cancer patients receiving anthracycline-based chemotherapy. Support Care Cancer (2011) 0.88
Novel photodynamic diagnosis of bladder cancer: ex vivo fluorescence cytology using hypericin. Int J Oncol (2003) 0.87
GST-pi expression correlates with oxidative stress and apoptosis in breast cancer. Oncol Rep (2004) 0.87
Mucin extravasation in breast core biopsies--clinical significance and outcome correlation. Histopathology (2009) 0.87
Parkin enhances the expression of cyclin-dependent kinase 6 and negatively regulates the proliferation of breast cancer cells. J Biol Chem (2010) 0.87
Breast cancer stem cells: an update. J Clin Pathol (2013) 0.86
Expression of FGFR1 is an independent prognostic factor in triple-negative breast cancer. Breast Cancer Res Treat (2015) 0.86
Whole blood biomarkers of acute cardiac allograft rejection: double-crossing the biopsy. Transplantation (2010) 0.86
Ductal carcinoma in situ within phyllodes tumour: a rare occurrence. Pathology (2005) 0.86
XBP-1, a novel human T-lymphotropic virus type 1 (HTLV-1) tax binding protein, activates HTLV-1 basal and tax-activated transcription. J Virol (2008) 0.86
Ten-Year Trends in Direct Costs of COPD: A Population-Based Study. Chest (2015) 0.86